Brief: Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential Of Its Novel DM1 Genetacs As Treatment For Myotonic Dystrophy Type-1
08/09/2021 11:40
Sept 8 (Reuters) - Design Therapeutics Inc DSGN.O :
* DESIGN THERAPEUTICS ANNOUNCES POSITIVE PRECLINICAL DATA
HIGHLIGHTING DISEASE-MODIFYING POTENTIAL OF ITS NOVEL DM1
GENETACS AS A TREATMENT FOR MYOTONIC DYSTROPHY TYPE-1
* DESIGN THERAPEUTICS - NEW DATA DEMONSTRATED ABILITY OF DM1
GENETACS TO POTENTLY, SELECTIVELY BLOCK EXPRESSION OF MUTANT
DMPK GENE IN DM1 PATIENT CELLS
Source text for Eikon: ID:nGNXbdlggr
Further company coverage: DSGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Design Therapeutics
See all newsDesign Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1